HCC-话题@MedSci

#HCC#

114篇内容 | 5772人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2097195, encodeId=b0e4209e195e7, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>非酒精性脂肪肝早期诊治可防治HCC, objectTitle=HCC, objectType=topic, longId=8545, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=67, createdTime=2022-10-29, rootId=0, userName=delianjihui, userId=a5281475204, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259575, encodeId=a10312595e530, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）, objectType=article, longId=739072, objectId=0c76e39072d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c76e39072d5, replyNumber=0, likeNumber=103, createdTime=2022-09-13, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c76e39072d5, moduleTitle=ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c76e39072d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259574, encodeId=08b412595e472, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, objectType=article, longId=739071, objectId=dd97e3907119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd97e3907119, replyNumber=0, likeNumber=103, createdTime=2022-09-13, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd97e3907119, moduleTitle=ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd97e3907119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259573, encodeId=762112595e356, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：TIPS加序贯系统疗法对HCC合并栓子相关症状性门脉高压患者的价值, objectType=article, longId=738562, objectId=96c1e3856277, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96c1e3856277, replyNumber=0, likeNumber=104, createdTime=2022-09-09, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96c1e3856277, moduleTitle=European Radiology：TIPS加序贯系统疗法对HCC合并栓子相关症状性门脉高压患者的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96c1e3856277)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259572, encodeId=21ea12595e21f, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=PLoS One：缘何瘦子也会得NASH-HCC？反式脂肪、胆固醇和果糖含量高的不健康饮食或是关键！, objectType=article, longId=737052, objectId=9c26e37052cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c26e37052cc, replyNumber=0, likeNumber=100, createdTime=2022-08-28, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c26e37052cc, moduleTitle=PLoS One：缘何瘦子也会得NASH-HCC？反式脂肪、胆固醇和果糖含量高的不健康饮食或是关键！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c26e37052cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259571, encodeId=b83f12595e102, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Sci Rep：每多一个代谢「筹码」，MAFLD-HCC就更近一步！患癌风险最高可增至5.9倍！, objectType=article, longId=736305, objectId=be1de363058b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be1de363058b, replyNumber=0, likeNumber=100, createdTime=2022-08-21, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be1de363058b, moduleTitle=Sci Rep：每多一个代谢「筹码」，MAFLD-HCC就更近一步！患癌风险最高可增至5.9倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be1de363058b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259570, encodeId=82f012595e0e3, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：肝功能成像评分在预测HCC切除术后肝功能衰竭方面的价值, objectType=article, longId=734133, objectId=c6d9e34133ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6d9e34133ee, replyNumber=0, likeNumber=98, createdTime=2022-08-03, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6d9e34133ee, moduleTitle=European Radiology：肝功能成像评分在预测HCC切除术后肝功能衰竭方面的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6d9e34133ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259569, encodeId=c5a712595696a, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=J AM COLL RADIOL：高风险患者对HCC筛查有何自己的“偏爱”？, objectType=article, longId=731500, objectId=0416e31500be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0416e31500be, replyNumber=0, likeNumber=100, createdTime=2022-07-08, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0416e31500be, moduleTitle=J AM COLL RADIOL：高风险患者对HCC筛查有何自己的“偏爱”？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0416e31500be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259568, encodeId=24a312595685e, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology:钇-90放射栓塞治疗在HCC 中的应用, objectType=article, longId=729012, objectId=cb6ce2901219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb6ce2901219, replyNumber=0, likeNumber=139, createdTime=2022-06-11, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb6ce2901219, moduleTitle=European Radiology:钇-90放射栓塞治疗在HCC 中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb6ce2901219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259567, encodeId=b6c8125956e60, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=BMC Cancer：BCLC B期肝细胞癌（HCC）患者初始使用仑伐替尼治疗的疗效, objectType=article, longId=726452, objectId=a4efe2645295, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4efe2645295, replyNumber=0, likeNumber=87, createdTime=2022-05-11, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4efe2645295, moduleTitle=BMC Cancer：BCLC B期肝细胞癌（HCC）患者初始使用仑伐替尼治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4efe2645295)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259566, encodeId=5f9f125956602, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：微波消融与射频消融在包膜下HCC中的应用, objectType=article, longId=726274, objectId=9a34e2627408, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a34e2627408, replyNumber=0, likeNumber=127, createdTime=2022-05-08, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a34e2627408, moduleTitle=European Radiology：微波消融与射频消融在包膜下HCC中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a34e2627408)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259565, encodeId=1eba12595658c, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：MRE在评估HCC微血管侵犯中的应用, objectType=article, longId=724333, objectId=af8be24333f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af8be24333f4, replyNumber=0, likeNumber=90, createdTime=2022-04-17, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af8be24333f4, moduleTitle=European Radiology：MRE在评估HCC微血管侵犯中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af8be24333f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259564, encodeId=b23c125956463, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：放射学列线图在cHCC-CC和ICC术前鉴别中的应用, objectType=article, longId=724247, objectId=fd2ae2424773, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd2ae2424773, replyNumber=0, likeNumber=90, createdTime=2022-04-15, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd2ae2424773, moduleTitle=European Radiology：放射学列线图在cHCC-CC和ICC术前鉴别中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd2ae2424773)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259563, encodeId=6e661259563eb, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=晚期肝癌（HCC）诊疗现状调研, objectType=article, longId=301841, objectId=af21301841f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af21301841f8, replyNumber=0, likeNumber=80, createdTime=2022-03-30, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af21301841f8, moduleTitle=晚期肝癌（HCC）诊疗现状调研, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af21301841f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259562, encodeId=e9db12595622b, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：Gd-EOB-DTPA增强MRI，实现HCC微血管浸润的无创评估！, objectType=article, longId=300420, objectId=9aee30042036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aee30042036, replyNumber=0, likeNumber=81, createdTime=2022-03-11, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aee30042036, moduleTitle=European Radiology：Gd-EOB-DTPA增强MRI，实现HCC微血管浸润的无创评估！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aee30042036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259561, encodeId=606e1259561f4, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, objectType=article, longId=299277, objectId=87e42992e798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87e42992e798, replyNumber=0, likeNumber=86, createdTime=2022-02-22, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87e42992e798, moduleTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87e42992e798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259560, encodeId=d7371259560e9, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, objectType=article, longId=295066, objectId=890729506606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890729506606, replyNumber=0, likeNumber=92, createdTime=2022-02-04, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890729506606, moduleTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890729506606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259559, encodeId=45d4125955949, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效, objectType=article, longId=294717, objectId=7d23294e17f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d23294e17f3, replyNumber=0, likeNumber=75, createdTime=2022-01-27, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d23294e17f3, moduleTitle=Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d23294e17f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259557, encodeId=0c56125955ee6, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=European Radiology：深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值, objectType=article, longId=293038, objectId=658829303868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=658829303868, replyNumber=0, likeNumber=96, createdTime=2021-12-30, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=658829303868, moduleTitle=European Radiology：深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=658829303868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1259556, encodeId=888f1259556ce, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, objectTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, objectType=article, longId=292954, objectId=a2d3292954c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2d3292954c0, replyNumber=0, likeNumber=64, createdTime=2021-12-29, rootId=0, userName=jiyangfei, userId=8e4c53, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2d3292954c0, moduleTitle=Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2d3292954c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HCC

2020-05-29

delianjihui (审核中...)

前往app查看评论内容

#HCC#非酒精性脂肪肝早期诊治可防治HCC

2022-10-29

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

ESMO 2022：替雷利珠单抗作为不可切除HCC一线治疗显示出非劣效于索拉非尼的OS获益（RATIONALE 301研究）

2022-09-13

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

ESMO 2022：双艾组合卡瑞利珠单抗联合阿帕替尼可显著改善不可切除HCC的生存期（SHR-1210-III-310研究）

2022-09-13

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：TIPS加序贯系统疗法对HCC合并栓子相关症状性门脉高压患者的价值

2022-09-09

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

PLoS One：缘何瘦子也会得NASH-HCC？反式脂肪、胆固醇和果糖含量高的不健康饮食或是关键！

2022-08-28

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Sci Rep：每多一个代谢「筹码」，MAFLD-HCC就更近一步！患癌风险最高可增至5.9倍！

2022-08-21

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：肝功能成像评分在预测HCC切除术后肝功能衰竭方面的价值

2022-08-03

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

J AM COLL RADIOL：高风险患者对HCC筛查有何自己的“偏爱”？

2022-07-08

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology:钇-90放射栓塞治疗在HCC 中的应用

2022-06-11

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

BMC Cancer：BCLC B期肝细胞癌（HCC）患者初始使用仑伐替尼治疗的疗效

2022-05-11

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：微波消融与射频消融在包膜下HCC中的应用

2022-05-08

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：MRE在评估HCC微血管侵犯中的应用

2022-04-17

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：放射学列线图在cHCC-CC和ICC术前鉴别中的应用

2022-04-15

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

晚期肝癌（HCC）诊疗现状调研

2022-03-30

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：Gd-EOB-DTPA增强MRI，实现HCC微血管浸润的无创评估！

2022-03-11

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS

2022-02-22

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后

2022-02-04

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Cancers：经动脉放射栓塞术(TARE)治疗不可切除肝细胞癌（HCC）安全有效

2022-01-27

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

European Radiology：深卷积神经网络在预测HCC患者术前微血管浸润和临床预后方面的价值

2021-12-30

jiyangfei (审核中...)

前往app查看评论内容

#HCC#

Front Oncol：TACE联合仑伐替尼(TACE- L) vs TACE联合索拉非尼(TACE- S)治疗肝细胞癌(HCC)伴有门静脉癌栓(PVTT)患者的疗效和安全性

2021-12-29

科室
- - 订阅+
  - 更多科室
工具
服务